Forty-two percent of all deaths in the United States are related to cardiovascular disease (CVD). According to the Global Cardiovascular Drugs Market Forecast, by 2030 the number of deaths from CVD will rise to 23.6 million per year in the U.S. alone. Along with increased deaths, spending on drugs to treat CVD as well as related hospital stays, home health care and lost productivity will also…
Flow cytometry has proved an invaluable diagnostic tool for leukaemia and lymphoma for almost three decades. Now, however, this is evolving in applications to seek out residual disease in cases and in fusion with molecular testing to advance its diagnostic potential. However, although recognised as fast, flexible and accurate, flow cytometry suffers from a lack of standardisation, according to…
It is non-invasive, delivers a chance of early diagnosis, prognostic information and sequential monitoring, and, believes Professor Francesco Salvatore, the enormous potential of liquid biopsies has still to be reached. However, the positive results obtained so far have ‘opened the door to a promising new multi-faceted group of tumour markers, at present collectively designated “liquid…
A commonly used biomarker of kidney disease may also indicate lung problems, particularly COPD, or chronic obstructive pulmonary disease, according to new research published online in the American Thoracic Society’s American Journal of Respiratory and Critical Care Medicine. In “Albuminuria, Lung Function Decline, and Risk of Incident COPD: the NHLBI Pooled Cohorts Study,” Elizabeth C.…
Researchers at Cleveland Clinic, University of Oxford, and University of Erlangen have identified a novel imaging biomarker – and found it can be used to predict all-cause and cardiac mortality by measuring inflammation of fatty tissue surrounding the coronary arteries.
Taking a biopsy of a brain tumor is a complicated and invasive surgical process, but a team of researchers at Washington University in St. Louis is developing a way that allows them to detect tumor biomarkers through a simple blood test. Hong Chen, a biomedical engineer, and Eric C. Leuthardt, MD, a neurosurgeon, led a team of engineers, physicians and researchers who have developed a…
ProteoMediX AG announced results from a retrospective study that showed the correlation of its prostate cancer diagnosis test with cancer aggressiveness in patients scheduled for prostate biopsies. The study findings presented at the 2018 European Association of Urology (EAU) congress in Copenhagen, Denmark showed that the test has the potential to avoid a large number of biopsies. “Correlation…
For the first time, scientists at Wake Forest Baptist Medical Center have been able to measure a specific molecule indicative of osteoarthritis and a number of other inflammatory diseases using a newly developed technology. This preclinical study used a solid-state nanopore sensor as a tool for the analysis of hyaluronic acid (HA). HA is a naturally occurring molecule that is involved in tissue…
New information on dementia biomarkers is emerging, as increasing results from population studies become available. However, although the list of risk factors lengthens, the value of these predictors, and more generally the cause of disease, remain to be determined, according to Gabriel Krestin, professor and chairman of the Department of Radiology & Nuclear Medicine at Erasmus MC, University…
One of the biggest challenges in treating prostate cancer is distinguishing men who have aggressive and potentially lethal disease from men whose cancer is slow-growing and unlikely to metastasize. For years, prostate-specific antigen (PSA) level, cancer grade and tumor stage have been used to sort prostate cancer patients into risk groups established by the National Comprehensive Cancer Network.…
Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and helps identify the location of the cancer. The test, called CancerSEEK, is a unique noninvasive, multianalyte test that simultaneously evaluates levels of eight cancer proteins and the presence of cancer gene mutations from circulating DNA in the blood. The test is aimed at…
Move over, lab-on-a-chip and lab-on-paper. There’s a new diagnostic technology in research labs that is gaining credibility. It is called lab-on-skin technology and some scientists are quite excited about how it might be used for a variety of clinical purposes. A recent story published in ACS Nano titled, “Lab-on-Skin: A Review of Flexible and Stretchable Electronics for Wearable Health…
A new marker that could be used to diagnose fatal breast cancer up to one year ahead of current methods has been identified in a study led by UCL. The study found that changes detected in a part of DNA which the researches named EFC#93 could suggest early signs of deadly breast cancer. Importantly, these abnormal patterns are present in blood serum before the cancer becomes detectable in the…
Providing insights into new cardiac testing methods, Professor Stefan Holdenrieder, Director of the Institute of Laboratory Medicine at Munich’s German Heart Centre, explained why biomarkers are a game changer in diagnostics.
BBI Solutions (BBI), immunoassay developer and reagent supplier, acquired Maine Biotechnology Services Inc. (MBS) in July 2017, adding antibody development to the firm’s end to end assay development services. This also strengthens BBI’s reagents antibodies portfolio, providing a wide range of high quality biomarkers for infectious disease.
Researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP) have identified a peptide that could lead to the early detection of Alzheimer’s disease (AD). The discovery, published in Nature Communications, may also provide a means of homing drugs to diseased areas of the brain to treat AD, Parkinson’s disease, as well as glioblastoma, brain injuries and stroke. “Our goal was to…
21st century challenges are multitudinous for all. Ageing populations, a changing disease burden; increasing obesity with associated morbidities – Type 2 diabetes, cancer and cardiovascular disease; climate change pressures and more. Any new build plan demands a low carbon footprint; respect for the environment is paramount. To capture all those elements, the plan to regenerate a previously 10…
Until now, familial breast cancer has only partly been linkable to genetic risk markers. In a worldwide joint effort, researchers have now identified further genetic variants that affect the risk for breast cancer. The study, which was conducted with participation of researchers from the German Cancer Research Center (DKFZ) and Heidelberg University Hospital, has now been published in Nature.…
Early-stage colon cancer patients could benefit in the future from specific genetic tests that forecast their prognosis and help them make the right decision regarding chemotherapy.
In a study well-timed for summer, vision scientists have found that eye freckles, dark spots on the colored part of the eye (iris), are more frequently found in people with higher lifetime exposure to sunlight. While not malignant, eye freckles could indicate the presence or risk of sunlight-triggered eye diseases like cataract or macular degeneration.
Pancreatic cancer is one of the most deadly types of malignancies, with a 5-year survival rate after late diagnosis of only about 5%. The majority of patients—about 80%—receive their diagnosis too late for surgery. The disease spreads quickly and resists chemotherapy. In short, there is an urgent need for diagnostic tools to identify this cancer in its earliest stages.
A Fred Hutchinson Cancer Research Center study, led by epidemiologist Dr. Parveen Bhatti, found that night shift work is associated with reduced ability to repair DNA lesions. Over time, DNA damage that is not repaired will cause mutations that can lead to cancer.
Ares Genetics GmbH, a wholly-owned subsidiary of Curetis GmbH and a developer of pioneering solutions for the detection of genetic resistances in pathogens, announced that the project "GEAR - Predicting Antibiotic Resistances with Genetic Data" has been awarded in the competition "Landmarks in the Land of Ideas".
Cancer biomarker testing represents an important element of the clinical biochemistry service, yet progress in this area in the last two decades has been slow.
For almost three quarters of hepatocellular carcinoma (HCC) patients in Europe it is too late for curative treatment because the disease is often only diagnosed at a very advanced stage. Interviewed Professor Guido Gerken MD, Director of the Department for Gastroenterology and Hepatology at University Hospital Essen, about improved and timelier diagnostic capabilities that have already been…